8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
MBX Biosciences, Inc. Common Stock(MBX)Earnings, Financials & Key Ratios
MBX•NASDAQ
$52.31
Price updated Jun 27, 2026
AboutMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Show more
- Revenue$0
- EBITDA-$98M-43.9%
- Net Income-$87M-40.5%
- EPS (Diluted)-2.38-28.6%
- ROE-27.76%+58.5%
MBX Price & Volume
MBX Biosciences, Inc. Common Stock (MBX) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical Burn Pressures Capital Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
"MBX Biosciences is currently in a high-intensity development phase, characterized by escalating R&D expenditures that have driven quarterly operating losses to $27.3 million as of 2026Q1. While the company maintains a negligible debt-to-equity ratio of 0.00, the rapid erosion of cash reserves from $223.1 million in 2025Q3 to $45.2 million in 2026Q1 suggests a precarious liquidity position. Investors should monitor the firm's ability to achieve clinical milestones before the current cash runway necessitates further dilutive equity financing."
Verdict Logic
the rapid depletion of cash reserves from $223.1 million in 2025Q3 to $45.2 million in 2026Q1 indicates a high risk of near-term shareholder dilution to fund ongoing clinical operations.
MBX Growth Metrics
MBX Biosciences, Inc. Common Stock (MBX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.89%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0%
Return on Capital
10 Years-47.49%
5 Years-47.49%
3 Years-43.19%
Last Year-31.27%
MBX Recent Earnings
MBX Biosciences, Inc. Common Stock (MBX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/10 qtrs (86%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.51+17.7%
$0.62
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.49+23.4%
$0.64
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.63+13.7%
$0.73
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.58+24.7%
$0.77
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.51vs $0.62+17.7% | — |
| Q2 2026 | Mar 12, 2026 | $0.49vs $0.64+23.4% | — |
| Q4 2025 | Nov 6, 2025 | $0.63vs $0.73+13.7% | — |
| Q3 2025 | Aug 7, 2025 | $0.58vs $0.77+24.7% | — |
Based on last 10 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for MBX Biosciences, Inc. Common Stock (MBX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $52.31 | $1.76B | -21.98 | — | — | -27.76% | — | |
| $18.40 | $1.13B | -4.95 | — | — | -51.45% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $1.70 | $117.59M | -0.80 | — | — | -59.89% | — | |
| $3.38 | $14.64M | -3.10 | 3.7% | -264.73% | -62.1% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — |
Compare MBX vs Peers
MBX Biosciences, Inc. Common Stock (MBX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MBX SEC Filings & Documents
MBX Biosciences, Inc. Common Stock (MBX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MBX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MBX Frequently Asked Questions
MBX Biosciences, Inc. Common Stock (MBX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is MBX profitable?
MBX Biosciences, Inc. Common Stock (MBX) reported a net loss of $86.6M for fiscal year 2025.
Dividend & Returns
What is MBX's return on equity?
MBX Biosciences, Inc. Common Stock (MBX) has a return on equity (ROE) of -27.8%. Negative ROE indicates the company is unprofitable.
What is MBX Biosciences, Inc. Common Stock's free cash flow?
MBX Biosciences, Inc. Common Stock (MBX) had negative free cash flow of $79.8M in fiscal year 2025, likely due to heavy capital investments.